Priftin® is the only pharmaceutical drug containing rifapentine available in the US.  Some parts of the United States have indicated difficulty in accessing the drug.  The U.S. Food and Drug Administration (FDA) has it listed as on allocation with intermittent supply as a result of an unexpected demand increase for Priftin.  

Sanofi has substantially increased the production volume of Priftin and is working to increase its manufacturing capacity but expects that the sharp ramp up after years of stable, low demand will create tension in the delivery schedule. Sanofi will do its best effort to meet demand in 2020 and is closely monitoring the distribution channel inventory to help ensure Priftin availability to customers.  

The anticipated arrival of Generic competitors on donor-funded markets outside of the US will be expected to increase the availability of rifapentine in the coming months that may bring some relief for the overall supply situation.